Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) (2014) Cronin K SEER Cancer Statistics Review, 1975–2011, National Cancer Institute, Bethesda, Md, USA, 2013, based on November 2013 SEER data submission, posted to the SEER web site http://seer.cancer.gov/csr/1975_2011/. Accessed 25 July 2022
Veness MJ, Porter GS, Morgan GJ (2004) Anaplastic thyroid carcinoma: dismal outcome despite current treatment approach. ANZ J Surg 74(7):559–562. https://doi.org/10.1111/j.1445-2197.2004.03062.x
Smallridge RC, Ain KB, Asaetal SL (2012) American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22(11):1104–1139. https://doi.org/10.1089/thy.2012.0302
Busnardo B, Daniele O, Pelizzo MR, Mazzarotto R, Nacamulli D, Devido D, Mian C, Girelli ME (2000) A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients. J Endocrinol Invest 23(11):755–761. https://doi.org/10.1007/BF03345066
Article CAS PubMed Google Scholar
Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivey JM, Duh QY, Clark OH (2001) Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 91(12):2335–2342
Article CAS PubMed Google Scholar
Stavas MJ, Shinohara ET, Attia A, Ning MS, Friedman JM, Cmelak AJ (2014) Short course high dose radiotherapy in the treatment of anaplastic thyroid carcinoma. J Thyroid Res 2014:764281. https://doi.org/10.1155/2014/764281
Article PubMed PubMed Central Google Scholar
De Leo S, Trevisan M, Fugazzola L (2020) Recent advances in the management of anaplastic thyroid cancer. Thyroid Res 13(1):17. https://doi.org/10.1186/s13044-020-00091-w
Article CAS PubMed PubMed Central Google Scholar
Harari PM, Huang SM (2000) Modulation of molecular targets to enhance radiation. Clin Cancer Res 6(2):323–325
Lane AA, Chabner BA (2009) Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27(32):5459–5468. https://doi.org/10.1200/JCO.2009.22.1291
Article CAS PubMed Google Scholar
Marks PA, Xu WS (2009) Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 107(4):600–608. https://doi.org/10.1002/jcb.22185
Article CAS PubMed PubMed Central Google Scholar
Ranganna K, Selvam C, Shivachar A, Yousefipour Z (2020) Histone deacetylase inhibitors as multitarget-directed epi-drugs in blocking PI3k oncogenic signaling: a polypharmacology approach. Int J Mol Sci 21(21):8198. https://doi.org/10.3390/ijms21218198
Article CAS PubMed PubMed Central Google Scholar
Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, Chiappori A, Sullivan D, Daud A (2009) Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Clin Trial Br J Cancer 101(7):1044–1050. https://doi.org/10.1038/sj.bjc.6605293
Groselj B, Sharma NL, Hamdy FC, Kerr M, Kiltie AE (2013) Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair. Br J Cancer 108:748–754. https://doi.org/10.1038/bjc.2013.21
Article CAS PubMed PubMed Central Google Scholar
Moertl S, Payer S, Kell R, Winkler K, Anastasov N, Atkinson MJ (2019) Comparison of radiosensitization by HDAC Inhibitors CUDC-101 and SAHA in pancreatic cancer cells. Int J Mol Sci 20(13):3259. https://doi.org/10.3390/ijms20133259
Article CAS PubMed PubMed Central Google Scholar
van Breemen MS, Rijsman RM, Taphoorn MJ, Walchenbach R, Zwinkels H, Vecht CJ (2009) Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol 256(9):1519–1526. https://doi.org/10.1007/s00415-009-5156-9
Zhu MM, Li HL, Shi LH, Chen XP, Luo J, Zhang ZL (2017) The pharmacogenomics of valproic acid. J Hum Genet 62(12):1009–1014. https://doi.org/10.1038/jhg.2017.91
Article CAS PubMed Google Scholar
Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20(24):6969–6978. https://doi.org/10.1093/emboj/20.24.6969
Article CAS PubMed PubMed Central Google Scholar
Blaheta RA, Michaelis M, Driever PH, Cinatl JJ (2005) Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 25:383–397. https://doi.org/10.1002/med.20027
Article CAS PubMed Google Scholar
Cinatl JJ, Cinatl J, Scholz M, Driever PH, Henrich D, Kabickova H, Vogel JU, Doerr HW, Kornhuber B (1996) Antitumor activity of sodium valproate in cultures of human neuroblastomacells. Anticancer Drugs 7:766–773. https://doi.org/10.1097/00001813-199609000-00008
Driever PH, Knüpfer MM, Cinatl J, Wolff JEA (1999) Valproic acid for the treatment of pediatric malignant glioma. Klin Padiatr 211:323–328. https://doi.org/10.1055/s-2008-1043809
Article CAS PubMed Google Scholar
Michaelis M, Doerr HW, Cinatl J (2007) Valproic acid as anti-cancer drug. Current Pharmaceut Des 13:3378–3393
Catalano MG, Fortunati N, Pugliese M, Costantino L, Poli R, Bosco O, Boccuzzi G (2005) Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 90(3):1383–1389. https://doi.org/10.1210/jc.2004-1355
Article CAS PubMed Google Scholar
Fortunati N, Catalano MG, Arena K, Brignardello E, Piovesan A, Boccuzzi G (2004) Valproic acid induces the expression of the Na+/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 89(2):1006–1009. https://doi.org/10.1210/jc.2003-031407
Article CAS PubMed Google Scholar
Karagiannis TC, El-Osta A (2006) Modulation of cellular radiation responses by histone deacetylase inhibitors. Oncogene 25(28):3885–3893. https://doi.org/10.1038/sj.onc.1209417
Article CAS PubMed Google Scholar
Makita N, Ninomiya I, Tsukada T, Okamoto K, Harada S, Nakanuma S, Sakai S, Makino I, Kinoshita J, Hayashi H, Katsunobu O, Hisatoshi N, Tomoharu M, Hidehiro T, Hiroyuki T, Sachio F, Tetsuo O (2015) Inhibitory effects of valproic acid in DNA double-strand break repair after irradiation in esophageal squamous carcinoma cells. Oncol Rep 34(3):1185–1192. https://doi.org/10.3892/or.2015.4089
Article CAS PubMed Google Scholar
Luo Y, Wang H, Zhao XP, Dong X, Zhang FM, Guo G, Guo WXW, Powell SN, Feng ZH (2016) Valproic acid causes radiosensitivity of breast cancer cells via disrupting the DNA repair pathway. Toxicol Res (Cam) 5(3):859–870. https://doi.org/10.1039/c5tx00476d
Van Oorschot B, Granata G, Franco S, Cate R, Rodermond HM, Todaro M, Medema JP, Franken NAP (2016) Targeting DNA double strand break repair with hyperthermia and DNA-PKCS inhibition to enhance the effect of radiation treatment. Oncotarget 7:65504–65513. https://doi.org/10.1863/oncotarget.11798
Article PubMed PubMed Central Google Scholar
Chinnaiyan P, Cerna D, Burgan WE, Beam K, Williams ES, Camphausen K, Tofilon PJ (2008) Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res 14:5410–5415. https://doi.org/10.1158/1078-0432.CCR-08-0643
Article CAS PubMed PubMed Central Google Scholar
Perona M, Thomasz L, Rossich L, Rodriguez C, Pisarev MA, Rosemblit C, Cremaschi GA, Dagrosa MA, Juvenal GJ (2018) Radiosensitivity enhancement of human thyroid carcinoma cells by the inhibitors of histone deacetylase sodium butyrate and valproic acid. Mol Cell Endocrinol 478:141–150. https://doi.org/10.1016/j.mce.2018.08.007
Article CAS PubMed Google Scholar
Barker CA, Bishop AJ, Chang M, Beal K, Chan TA (2013) Valproic acid use during radiation therapy for glioblastoma associated with improved survival. Int J Radiat Oncol Biol Phys 86(3):504–509. https://doi.org/10.1016/j.ijrobp.2013.02.012
Article CAS PubMed PubMed Central Google Scholar
Krauze AV, Myrehaug SD, Chang MG, Holdford DJ, Smith S, Shih J, Tofilon PJ, Fine HA, Camphausen K (2015) A phase 2 study of concurrent radiation therapy, Temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma. Int J Radiat Oncol Biol Phys 92(5):986–992. https://doi.org/10.1016/j.ijrobp.2015.04.038
Article CAS PubMed PubMed Central Google Scholar
Tennvall J, Lundell G, Wahlberg P, Bergenfelz A, Grimelius L, Akerman M, Hjelm Skog AL, Wallin G (2002) Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 86(12):1848–1853. https://doi.org/10.1038/sj.bjc.6600361
Article CAS PubMed PubMed Central Google Scholar
Chateauvieux S, Morceau F, Dicato M, Diederich M (2010) Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010:479364. https://doi.org/10.1155/2010/479364
Article CAS PubMed PubMed Central Google Scholar
Noguchi H, Yamashita H, Murakami T, Hirai K, Noguchi Y, Maruta J, Yokoi T, Noguchi S (2009) Successful treatment of anaplastic thyroid carcinoma with a combination of oral valproic acid, chemotherapy, radiation and surgery. Endocr J 56:245–249. https://doi.org/10.1507/endocrj.k08e-016
留言 (0)